Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction: A phase II dose escalation, randomized, double-blind study

European Heart Journal

Volumn 21, Issue 18, 2000, Pages 1530-1536

  Ronner, E ^a   Van Kesteren, H A M ^b   Zijnen, P ^c   Altmann, E ^d   Molhoek, P G ^e   Van Der Wieken, L R ^f   Cuffie Jackson, C A ^g   Neuhaus, K L ^h   Simoons, M L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Maria Hospital TIlburg   (Netherlands)

^c CPRLab   (Netherlands)

^d ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^g MERCK RESEARCH LABORATORIES   (United States)

^h KLINIKUM KASSEL   (Germany)

Author keywords

Angiography; Eptifibatide; Myocardial infarction; Platelet aggregation inhibitors; Streptokinase; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; PLACEBO; STREPTOKINASE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ASPIRIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0033817072     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.2035     Document Type: Article

References (28)

1. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
2. Platelet glycoprotein IIb/IIIa receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention
3. Randomized trial of a glycoprotein IIb/IIIa platelet receptor blocker in refractory unstable angina
4. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
7. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
8. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
9. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial
10. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II
11. Eptifibatide enhances fibrinolysis and prevents acute arterial reoclusion following thrombolysis in a canine anodal current model with high-grade stenosis
12. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet glycoprotein IIb/IIIa antibody in a canine preparation
13. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet glycoprotein IIb/IIIa antibody
14. Conjunctive use of platelet glycoprotein IIb/IIIa antagonists and thrombolytic therapy for acute myocardial infarction
15. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial
16. The effects of tissue plasminogen activator, streptokinase or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction
17. The thrombolysis in myocardial infarction (TIMI) trial
18. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
19. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
20. Acute myocardial infarction: Pre-hospital and in-hospital management
21. Thrombolysis in myocardial infarction (TIMI) trial - Phase 1: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
22. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction
23. Clinical value of 12-lead electrocardiogram after succesfull reperfusion therapy for acute myocardial infarction
24. Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolyis in myocardial infarction (TIMI) 14 trial
25. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus alteplase
26. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: The COMPASS equivalence trial. Comparison trial of saruplase and streptokinase (COMASS) investigators
27. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
28. Combining thrombolytics with the platelet glycoprotein IIb/IIIa inhibitor lamifiban; results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM trial)